QUESTIONSTargeting the Ubiquitin System for Drug Discovery
Venue: Park Hyatt at the Bellevue
Location: Philadelphia, Pennsylvania, United States
| Event Date/Time: Jun 21, 2004 | End Date/Time: Jun 22, 2004 |
| Registration Date: May 21, 2004 | |
| Early Registration Date: Apr 30, 2004 |
Report as SpamDescription
With the recent clinical validation of VELCADE, the first proteasome inhibitor to be approved by the FDA for cancer therapy, interest has exploded in the ubiquitin-proteasome pathway field. In addition to cancer, research in under way for the potential of therapeutic intervention in many other disease areas such as antiviral, osteoporosis and muscular atrophy.
